Literature DB >> 30149318

Activity-Based Costing and Time-Driven Activity-Based Costing for Assessing the Costs of Cancer Prevention, Diagnosis, and Treatment: A Systematic Review of the Literature.

Rafael J Vargas Alves1, Ana P Beck da Silva Etges2, Giácomo Balbinotto Neto3, Carisi Anne Polanczyk4.   

Abstract

BACKGROUND: A review of the literature on economic analyses in cancer (prevention, diagnosis, and treatment) using activity-based costing (ABC) or time-driven activity-based costing (TDABC) for measuring costs and to examine how these approaches have been applied to assess and manage cancer costs.
METHODS: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We conducted a search for studies that used ABC or TDABC to calculate the cost of cancer in prevention, diagnosis, and treatment. Only English- and Portuguese-language articles were retrieved from Medline, Lilacs, ScieLO, and Embase (January 1990 to August 2016).
RESULTS: In total, 421 studies were evaluated. However, only 27 papers were included. The first publications were from the early 2000s, but most of the studies were published in 2016 (n = 10). Most of the studies were carried out in the United States (n = 6) and Belgium (n = 6). Cancer treatment was the major focus of all studies (n = 20), followed by screening programs evaluations (n = 4) and diagnosis (n = 3). Among treatment modalities, economic analysis of radiotherapy was the most common topic of study. Retrospective clinical data represented 57.6% of the studies. More than 50% of the studies presented unspecified economic analysis. The hospital perspective was the most prevalent perspective among the studies (46.1%).
CONCLUSIONS: ABC and TDABC economic analyses are a promising area of studies in oncology costs.
Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABC; Cancer; Economic; TDABC

Mesh:

Year:  2018        PMID: 30149318     DOI: 10.1016/j.vhri.2018.06.001

Source DB:  PubMed          Journal:  Value Health Reg Issues        ISSN: 2212-1099


  7 in total

Review 1.  Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature.

Authors:  Amy J Davidoff; Kaitlin Akif; Michael T Halpern
Journal:  J Natl Cancer Inst Monogr       Date:  2022-07-05

2.  The healthcare costs of treating human papillomavirus-related cancers in Norway.

Authors:  Hannah Hylin; Helene Thrane; Kine Pedersen; Ivar S Kristiansen; Emily A Burger
Journal:  BMC Cancer       Date:  2019-05-07       Impact factor: 4.430

3.  A standardized framework to evaluate the quality of studies using TDABC in healthcare: the TDABC in Healthcare Consortium Consensus Statement.

Authors:  Ana Paula Beck da Silva Etges; Carisi Anne Polanczyk; Richard D Urman
Journal:  BMC Health Serv Res       Date:  2020-12-01       Impact factor: 2.655

4.  Cutaneous melanoma: cost of illness under Brazilian health system perspectives.

Authors:  Cassia Rita Pereira da Veiga; Claudimar Pereira da Veiga; Alceu Souza; Alberto Julius Alves Wainstein; Andreia Cristina de Melo; Ana Paula Drummond-Lage
Journal:  BMC Health Serv Res       Date:  2021-03-29       Impact factor: 2.655

5.  COVID-19 and hospital management costs: the Italian experience.

Authors:  Emanuela Foglia; Lucrezia Ferrario; Fabrizio Schettini; M Beatrice Pagani; Martina Dalla Bona; Emanuele Porazzi
Journal:  BMC Health Serv Res       Date:  2022-08-04       Impact factor: 2.908

6.  Clinical experience and cost evaluation of magnetic resonance imaging -only workflow in radiation therapy planning of prostate cancer.

Authors:  Jani Keyriläinen; Olli Sjöblom; Sonja Turnbull-Smith; Taru Hovirinta; Heikki Minn
Journal:  Phys Imaging Radiat Oncol       Date:  2021-07-17

7.  Applying Simulation Optimization to Minimize Drug Inventory Costs: A Study of a Case Outpatient Pharmacy.

Authors:  Chia-Nan Chen; Chin-Hui Lai; Guan-Wei Lu; Ching-Chun Huang; Le-Jean Wu; Hui-Chuan Lin; Ping-Shun Chen
Journal:  Healthcare (Basel)       Date:  2022-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.